Share on StockTwits

Infinity Pharmaceuticals (NASDAQ:INFI)‘s stock had its “buy” rating restated by analysts at Stifel Nicolaus in a research report issued to clients and investors on Wednesday, Analyst RN reports. They currently have a $20.00 target price on the stock, down from their previous target price of $25.00. Stifel Nicolaus’ target price would suggest a potential upside of 126.76% from the company’s current price.

Shares of Infinity Pharmaceuticals (NASDAQ:INFI) traded down 2.54% on Wednesday, hitting $8.82. 837,170 shares of the company’s stock traded hands. Infinity Pharmaceuticals has a 52-week low of $8.72 and a 52-week high of $36.23. The stock has a 50-day moving average of $10.94 and a 200-day moving average of $12.93. The company’s market cap is $425.8 million.

Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by $0.04. On average, analysts predict that Infinity Pharmaceuticals will post $-3.31 earnings per share for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Infinity Pharmaceuticals in a research note on Wednesday. They now have a $20.00 price target on the stock, down previously from $24.00. Separately, analysts at Jefferies Group upgraded shares of Infinity Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday. They now have a $13.00 price target on the stock, down previously from $15.00. Finally, analysts at Nomura cut their price target on shares of Infinity Pharmaceuticals from $17.00 to $12.00 in a research note on Wednesday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. Infinity Pharmaceuticals has an average rating of “Hold” and an average target price of $19.80.

Infinity Pharmaceuticals, Inc (NASDAQ:INFI) is a drug discovery and development company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.